Navigation Links
Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal


Focus On AV411's Unique Mechanism of Action and Broad Potential for the Treatment of Neurological Conditions

ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for the treatment of neurological conditions, announced today that Expert Opinion on Investigational Drugs has published an article featuring Avigen's pipeline product, AV411 (ibudilast), a potential first-in-class, non-opioid oral treatment for the management of multiple neurological indications, including neuropathic pain and opioid withdrawal.

"The work on this medication demonstrates the potential of basic neuroscience research, yielding a novel approach to the management of neuropathic pain, enhancement of opiate analgesia, and the management of opiate withdrawal. It's my hope that all these possible avenues will be pursued in addition to further basic research that may uncover other clinical applications of this putative medication," stated Frank Vocci, M.D., Director, Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health.

According to the National Pain Foundation, neuropathic pain affects up to four million people in the United States. Existing medications, such as opioids, often have modest efficacy in controlling chronic pain because they are targeted specifically to act on neurons. Additionally, opioid use can lead to dependence and withdrawal. Avigen scientists, led by Kirk Johnson, Ph.D., Vice President of Research and Development, in collaboration with researchers at the University of Colorado, Boulder, and the University of Adelaide, Australia, are developing AV411 to address this unmet medical need of controlling chronic pain, while avoiding opioid tolerance and withdrawal.

AV411, in early phase II clinical development in patients with diabetic neuropathic pain, modulat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
7. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
8. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
9. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
10. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
Post Your Comments:
(Date:12/2/2008)...ire/ -- Horizon Therapeutics, Inc., a,privately h...t two pivotal,Phase 3 trials evaluating its lead ...ll primary endpoints. HZT-501, a novel, proprietar...ofen and famotidine, demonstrated a,statistically...roidal,anti-inflammatory drug (NSAID)-induced upp...
(Date:12/1/2008)...c. 2 A study has found ...chnique for imaging the breast, is not affected by...s, two factors that limit the effectiveness of sta...ults will be presented today at the annual meeting...A). , , "The ability of PEM to detect canc...
(Date:12/1/2008).../ -- S*BIO Pte Ltd today announced the initiation ...and orally-active JAK2 inhibitor, in leading medic...idiopathic myelofibrosis (CIMF). , , The t...bility of SB1518 in patients with CIMF and is expe... of the study will assess the safety profile and e...
(Date:12/1/2008)...1 gene is a two-way switch that, if turned off, ca...d so that they lose their identity and become more...Tenn., Dec. 1 Scientis...iscovered that a certain differentiated cell type ...s the constant expression of a gene called Prox1 ...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 1Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 1SI International Awarded 244 Million Army HRsolutions Task Order 3781 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 3Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 1CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 3CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 4
...oequivalent Pharmacokinetics With Reduced Risk,of ..., April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTR...arch and,development company focused on commercial...ment of cancer and infectious diseases,today anno...netic,testing of ANX-514 (docetaxel emulsion) in a...
..., April 25, 2007 - Basilea Pharmaceutica Ltd.,(SWX...ing that,patients with severe chronic hand eczema ...n two previous randomized clinical,trials, alitret...,chronic hand eczema in patients refractory to top...hat patients responsive to initial,treatment with ...
Other Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
(Date:12/2/2008)... ORLANDO, Fla., Dec. 2 MEDai, Inc...care solutions provider, has added a new module,t...ons. The new stand-alone,module monitors a popul...delines and alerts stakeholders when there has bee...e Risk Navigator Guidelines(TM) provides,real-tim...
(Date:12/2/2008)... CHICAGO, Dec. 2 MedCommons annou...the EMC Open Systems Archive Solution for Healthca...lution for Healthcare,Organizations provides a mo...gregates and reconciles patient information, inclu...plications into a patient-centric archive. The,in...
(Date:12/2/2008)... VANCOUVER, Dec. 2 /PRNewswire-FirstCall/ - Respo...) announced the initiation of a clinical trial of ...yncytial Virus (RSV). Prospective data from the cl...ubmission to the U.S. Food and Drug Administration...et clearance of the 3M Rapid Detection RSV test fo...
(Date:12/2/2008)... At Least 10 New Cellular Therapies Will Launch O...cision Resources , , WALTHAM, Mass., Dec. 2...rld,s leading research and advisory firms for phar...ellular therapies drug market will experience robu...e, reaching $1.5 billion in 2017. According to the...
Breaking Medicine News(10 mins):Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 3Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 2Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 3Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 4Health News:Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017 2
... from LaTrobe University of Australia have found a...ciparum, the parasite responsible for causing mala...imaquine for treatment // helps in killing P. falc...ne drug. Chloroquine is a largely used drug in the...
...avoidance is the only way to prevent food allergy,...ions. Although an individual could be allergic to ...he following // eight foods i.e. cow’s milk, egg, ...ellfish, legumes (peanut and soy), cereals (wheat,...
...ne of the most common breathing problems encounter..., there has been a considerable increase in the in...n. // It has been estimated that nearly 196,000 ch...States every year with asthma attacks. A considera...
...atent rows over basmati and turmeric, India doesn'... certainly not when it comes to its ancient healin...task force appointed by the government for protect...tual property is fast completing the documentation...
Other Medicine News:Health News:Improved parent-physician communication to prevent hospitalizations for childhood asthma 2Health News:Yoga, ayurveda being documented to stop patent misuse 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: